Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.88 -0.6%	$3.83	$2.12 ▼ $5.80	$386.42M	1.99	1.52 million shs	1.80 million shs
BMEA Biomea Fusion	$1.88 +2.5%	$1.77	$1.29 ▼ $13.07	$110.39M	-0.14	1.34 million shs	268,824 shs
CMPX Compass Therapeutics	$3.29 +4.3%	$2.87	$1.19 ▼ $4.08	$453.98M	1.49	1.40 million shs	493,384 shs
CRVS Corvus Pharmaceuticals	$5.49 -0.8%	$4.42	$2.54 ▼ $10.00	$404.96M	0.42	795,513 shs	582,548 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+1.04%	+1.30%	-6.02%	+42.86%	-12.36%
BMEA Biomea Fusion	+1.10%	+6.40%	0.00%	+31.65%	-76.60%
CMPX Compass Therapeutics	+4.30%	+15.81%	-0.94%	+50.00%	+138.64%
CRVS Corvus Pharmaceuticals	+1.65%	+6.33%	+17.62%	+46.56%	+34.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	2.2411 of 5 stars	3.4	3.0	4.0	0.0	0.0
BMEA Biomea Fusion	3.5526 of 5 stars	4.6	3.0	1.6	2.5	0.6
CMPX Compass Therapeutics	2.8013 of 5 stars	3.6	1.0	2.5	5.0	0.0
CRVS Corvus Pharmaceuticals	3.2223 of 5 stars	3.5	2.0	3.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$10.14	161.75% Upside
BMEA Biomea Fusion	3.17	Buy	$16.80	796.00% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	292.36% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	173.03% Upside

Current Analyst Ratings Breakdown

Latest BMEA, CMPX, AQST, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	AQST Aquestive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	6.71	N/A	N/A	($0.73) per share	-5.31
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.70	N/A	N/A	N/A	-147.38%	N/A	-63.87%	11/3/2025 (Estimated)
BMEA Biomea Fusion	-$138.43M	-$3.03	N/A	N/A	N/A	N/A	-243.95%	-140.74%	11/4/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)

Latest BMEA, CMPX, AQST, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	-$0.14	+$0.04	-$0.14	$11.32 million	$10.00 million
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	3.53	3.18
BMEA Biomea Fusion	N/A	3.68	3.68
CMPX Compass Therapeutics	N/A	7.66	7.66
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
BMEA Biomea Fusion	96.72%
CMPX Compass Therapeutics	68.43%
CRVS Corvus Pharmaceuticals	46.64%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
BMEA Biomea Fusion	18.42%
CMPX Compass Therapeutics	29.80%
CRVS Corvus Pharmaceuticals	31.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.72 million	91.90 million	Optionable
BMEA Biomea Fusion	50	59.51 million	48.55 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	51.19 million	Optionable

BMEA, CMPX, AQST, and CRVS Headlines

Recent News About These Companies

EntryPoint Capital LLC Decreases Stake in Corvus Pharmaceuticals, Inc. $CRVS

August 27 at 4:27 AM | marketbeat.com

Cantor Fitzgerald Brokers Cut Earnings Estimates for CRVS

August 16, 2025 | marketbeat.com

What is HC Wainwright's Forecast for CRVS Q3 Earnings?

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Raise Earnings Estimates for CRVS

August 16, 2025 | americanbankingnews.com

HC Wainwright Has Bearish Estimate for CRVS FY2028 Earnings

August 15, 2025 | marketbeat.com

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

August 12, 2025 | seekingalpha.com

Corvus Pharmaceuticals (NASDAQ:CRVS) Raised to Hold at Wall Street Zen

August 10, 2025 | marketbeat.com

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Corvus (CRVS) Q2 Loss Beats Estimates

August 8, 2025 | aol.comA

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) top owners are retail investors with 48% stake, while 33% is held by institutions

August 5, 2025 | finance.yahoo.com

Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Cantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)

June 14, 2025 | theglobeandmail.com

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

June 11, 2025 | taiwannews.com.twT

Corvus Nicks up on Releasing Preclinical Trial Data

June 11, 2025 | baystreet.ca

3 Penny Stocks Wall Street Sees With 243% Upside

June 11, 2025 | 247wallst.com

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

June 4, 2025 | globenewswire.com

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

May 10, 2025 | marketwatch.com

Why Corvus Pharmaceuticals, Inc.’s (CRVS) Stock Is Up 29.85%

May 10, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA, CMPX, AQST, and CRVS Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.88 -0.03 (-0.64%)

As of 03:57 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Biomea Fusion NASDAQ:BMEA

$1.88 +0.05 (+2.46%)

As of 03:57 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Compass Therapeutics NASDAQ:CMPX

$3.28 +0.14 (+4.29%)

As of 03:57 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.49 -0.05 (-0.83%)

As of 03:56 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time